Alzinova AB
Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b study. The company also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, call… Read more
Alzinova AB (ALZ) - Total Liabilities
Latest total liabilities as of September 2025: Skr9.05 Million SEK
Based on the latest financial reports, Alzinova AB (ALZ) has total liabilities worth Skr9.05 Million SEK as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Alzinova AB - Total Liabilities Trend (2012–2024)
This chart illustrates how Alzinova AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Alzinova AB Competitors by Total Liabilities
The table below lists competitors of Alzinova AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tadmax Resources Berhad
KLSE:4022
|
Malaysia | RM548.86 Million |
|
Tel-Instrument Electronics Corp
OTCQB:TIKK
|
USA | $3.95 Million |
|
Acco Group Holdings Limited Ordinary Shares
NASDAQ:ACCL
|
USA | $1.72 Million |
|
Evion Group NL
AU:EVG
|
Australia | AU$788.25K |
|
Xpedra Resources Limited
AU:XPD
|
Australia | AU$2.48 Million |
|
Logismos Information Systems S.A
AT:LOGISMOS
|
Greece | €2.06 Million |
|
FG Financial Group
NASDAQ:FGF
|
USA | $23.52 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Alzinova AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alzinova AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alzinova AB (2012–2024)
The table below shows the annual total liabilities of Alzinova AB from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr9.40 Million | +0.77% |
| 2023-12-31 | Skr9.33 Million | +53.27% |
| 2022-12-31 | Skr6.09 Million | +89.09% |
| 2021-12-31 | Skr3.22 Million | -32.81% |
| 2020-12-31 | Skr4.79 Million | +8.40% |
| 2019-12-31 | Skr4.42 Million | +89.33% |
| 2018-12-31 | Skr2.33 Million | +0.26% |
| 2017-12-31 | Skr2.33 Million | +64.85% |
| 2016-12-31 | Skr1.41 Million | -9.79% |
| 2015-12-31 | Skr1.57 Million | +165.74% |
| 2014-12-31 | Skr589.25K | -19.06% |
| 2013-12-31 | Skr728.02K | +328.80% |
| 2012-12-31 | Skr169.78K | -- |